FGF-23 and Mineral Metabolism in Chronic Kidney Disease
Author Information
Author(s): Kosaku Nitta
Primary Institution: Tokyo Women's Medical University
Hypothesis
The increased levels of FGF-23 in chronic kidney disease are primarily the result of decreased renal clearance.
Conclusion
High serum FGF-23 concentrations predict more rapid disease progression in CKD patients and increased mortality in patients on maintenance hemodialysis.
Supporting Evidence
- High FGF-23 levels in patients starting hemodialysis predict 1-year mortality.
- FGF-23 levels were a significant independent predictor of CKD progression.
- Serum FGF-23 levels are independently related to aortic calcification in hemodialysis patients.
- Elevated FGF-23 levels are associated with increased mortality in long hemodialysis patients.
Takeaway
FGF-23 is a protein that helps control minerals in the body, and higher levels of it can mean kidney problems and a higher chance of dying for people on dialysis.
Methodology
The study involved reviewing existing literature and data on FGF-23 levels in CKD patients and their association with disease progression and mortality.
Potential Biases
Potential biases may arise from the observational nature of the studies reviewed.
Limitations
The study primarily relies on existing literature, which may have varying methodologies and sample sizes.
Participant Demographics
The study included patients with stages 1-4 CKD, both diabetic and nondiabetic.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website